Entest BioMedical Inc. is a biomedical research
company specializing in new procedures, treatments and medical devices that not only achieve measurable results, but also
improve the quality of life for patients. Entest prides itself on breaking away from the traditional approaches to cancer
treatment and mitigating the deleterious side effects of chemotherapy and radiation. Entest offers a novel and "personalized"
approach to cancer therapy that utilizes the body's own defense mechanisms. At the same time, the Company's focus on canine
applications provides a platform to launch near-term clinical trials and offers a much faster path to profitability than similar
biotech companies that are solely focused on treating the human population.
Entest BioMedical has established a solid foundation through its extensive network within the scientific community,
veterinarian hospitals, research facilities and various institutions. The cancer treatment technology, coupled with the Company's
strategic partners and joint ventures, provide a solid foundation for marketing Entest's canine applications, beginning with
the roll-out of ImenVax I, ImenVax II, and ImenVax III products.
Entest BioMedical sees the acquisition of veterinary clinics and the establishment of a veterinary oncology center
as cornerstones to its business model. Veterinary clinics are believed to bring near term revenue to the company, as well
as play a strong roll in product distribution as the Company brings products to market.
The veterinary oncology center will allow Entest to vertically integrate pet care, capturing revenue normally lost
to outside facilities. There is a perceived dynamic relationship between the veterinary clinics and the veterinary oncology
center. Veterinary clinics typically serve as general practice facilities, which normally refer cancer treatment to specialized
Veterinary Oncology Centers. Entest BioMedical Inc. intends to establish or purchase its own Veterinary Oncology Center to
service patients from veterinary clinics owned by Entest. This places Entest in a position of not only developing products
but controlling the distribution channel as well. It is the Company's goal to become the "Cleveland Clinic" of Veterinary
Oncology adhering to their "Pets first" company motto
Given the team's dedication and focus on the advancement of Immuno-Therapeutic Cancer Vaccine, Entest expects to
generate near-term revenue, while creating substantial value for shareholders.